Keywords
Neoplasm
Skin
Dermatology
Pleomorphic dermal sarcoma
Abstract
A pleomorphic dermal sarcoma (PDS) is considered a rare and poorly understood neoplasm of the skin.1 This has features similar to atypical fibroxanthoma (AFX).1 As well as the baseline similar characteristics to an AFX, a PDS also exhibits features of an infiltrative growth pattern which allows invasion of the subcutis, tumour necrosis and the possibility of lymphovascular invasion.2 These are more aggressive features than the more extensively reported AFX. There is a degree of metastatic potential associated with a PDS and hence early diagnosis and management with the appropriate multi-disciplinary team (MDT) is important to optimise the clinical prognosis. This case report will discuss a relatively rare diagnosis of a patient presenting with a PDS on the scalp and his management within the Oral and Maxillofacial Surgical (OMFS) Department, including consideration of his overall palliative care. Here, we will discuss the social, medical and physical implications of this diagnosis as well as considering the overall determinants of his quality of life (QoL).
References
Lonie S, Yau B, Henderson M, Gyorki D, Angel C, Webb A. Management of pleomorphic dermal sarcoma. ANZ J Surg. 2020;90(11):2322-2324. Available from: https://doi.org/10.1111/ans.15909
Tardío JC, Pinedo F, Aramburu JA, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol 2016;43:101–12. Available from: https://doi.org/10.1111/cup.12603
Ouyang Y-H Skin cancer of the head and neck. Semin Plast Surg. 2012;24(2):117-126. Available from: https://doi.org/10.1055/s-0030-1255329
Hishida T, Masai K, Kaseda K, Asakura K, Asamura H, Debulking surgery for malignant tumours: the current status, evidence and future perspectives. Jpn J Clin Oncol 2021;51(9):1349–1362. Available from: https://doi.org/10.1093/jjco/hyab107
Silberman AW. Surgical debulking of tumors. Surg Gynecol Obstet. 1982;155(4):577-85.
Soothill K, Morris SM, Thomas C, Harman JC, Francis B, McIllmurray MB. The universal, situational, and personal needs of cancer patients and their main carers. Eur J Oncol Nurs. 2003;7(1):5-13; discussion 14-6. Available from: https://doi.org/10.1054/ejon.2002.0226
Rogers SN, Semple C, Babb M, Humphris G. Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S49-S52. Available from: https://doi.org/10.1017/S0022215116000438
Saxena S, Orley J. Quality of life assessment: the world health organization perspective. Eur Psychiatry 1997;12(Supp3):263–6. Available from: https://doi.org/10.1016/S0924-9338(97)89095-5
Klein S, Quaas A, Noh K-W, et al. Integrative analysis of pleomorphic dermal sarcomas reveals fibroblastic differentiation and susceptibility to immunotherapy. Clini Cancer Res 2020;26(21):5638–5645. Available from: https://doi.org/10.1158/1078-0432.CCR-20-1899
Guest JF, Fuller GW, Vowden P. (2020) Cohort study evaluating the burden of wounds to the UK’s National Health Service in 2017/2018: Update from 2012/2013. BMJ Open 2020;10(12):e045253. Available from: https://doi.org/10.1136/bmjopen-2020-045253
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59–65